Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12153468 | 0.87 | SIGMAR1 (0.48) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL30261935 | 0.87 | SIGMAR1 (0.48) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL45191 | 0.80 | SIGMAR1 (0.43) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL28148719 | 0.78 | SIGMAR1 (0.41) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL714492 | 0.78 | ALDH1A1 (0.42) | MEN1KMT2AADRA2AADRA2BADRA2C | |
| SCHEMBL30685549 | 0.77 | MAPT (0.42) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12153469 | 0.77 | MAPT (0.42) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL15987689 | 0.76 | LMNA (0.41) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| Iodide SCHEMBL1928883 | 0.75 | MAPT (0.41) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL29843853 | 0.75 | MAPT (0.41) | SIGMAR1NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817806-B1 | PHENOTHAZINES-S-OXIDES AND S,S-DIOXIDES AS hole and excitonblockers for OLEDs | BASF SE (DE) | 2014-07-30 | — | — | EP | disclosed |
| US-8029919-B2 | Phenothiazines, S-oxides, and S,S-dioxides as well as phenoxazines as emitters for OLEDs | BASF AKTIENGESELLSCHAFT (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | BASF AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | US | disclosed |
| EP-1817806-A1 | PHENOTHAZINES, -S-OXIDES, AND S,S-DIOXIDES AS WELL AS PHENOXAZINES AS EMITTERS FOR OLEDS | BASF AKTIENGESELLSCHAFT (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006056465-A1 | PHENOTHIAZINES, -S-OXIDES, AND S,S-DIOXIDES AS WELL AS PHENOXAZINES AS EMITTERS FOR OLEDS | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100308714-A1 | Phenothiazines, S-Oxides, And S,S-Dioxides As Well As Phenoxazines As Emitters For Oleds | PPOX, SMOX, SORD | SIGMAR1 291/4885NPC1 3455/4885RAB9A 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.